Hanmi Pharm is examining the possibility of new indications with new drug candidates returned by multinational pharmaceutical company Eli Lilly. Hanmi Pharmaceutical announced on the 12th that it announced the interim results of phase 2 clinical trial of three-drug combination therapy, a follow-up study of the BTK inhibitor Poseltinib, at the European Society of Hematology recently held in Frankfurt, Germany. The safety and efficacy of the three-drug combination therapy including Poseltinib in relapsed and refractory diffuse large B-cell lymphoma were confirmed. Hanmi Pharmaceutical and Genome Opinion supported it, and Professor Byun Ja-min of the Department of Hematology and Oncology at Seoul National University Hos